# Regeneron Pharmaceuticals, Inc. (REGN) — Q3-2009 Earnings Results

**Report date:** 2009-11-03 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q3-2009

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Up 3.7%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.01 | N/A | +95.71% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management conveyed a sense of cautious optimism regarding the company's future. They emphasized their commitment to innovation and development.

**Key quotes:**

> Management expressed satisfaction with the EPS performance despite the lack of revenue guidance.

> They highlighted ongoing research and development efforts as a priority.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron's earnings report showed a significant positive surprise in EPS, which likely contributed to the stock's 3.7% increase. Investors may view the EPS beat as a sign of resilience, even without revenue figures or guidance. The management's focus on R&D suggests a long-term growth strategy, which could further influence investor sentiment.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q3-2009_